Full Text View
Tabular View
No Study Results Posted
Related Studies
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
This study has been terminated.
( Study completed )
Study NCT00203866   Information provided by University of Chicago

First Received on September 12, 2005.   Last Updated on February 12, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Renal Cell Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Renal Cell
More general conditions related to this trial
Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
G250 peptide
IL-2
Additional drug interventions recognized in this trial
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Antineoplastic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
University of Chicago


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services